Next Touch: BridGene Biosciences $28M Pipeline Trigger
BridGene just closed $28M Series B. Ping Cao needs chemoproteomics & clinical ops scale. Grab this battle card for your next touch and fill your pipeline fast.
Published on
Do not index
Do not index
🚀 Battle Card: BridGene Biosciences
Quick trigger:
👤 Decision Maker in the News
- Ping Cao, Ph.D., Co-Founder & CEO 📧 ping.cao@bridgenebio.com
💡 Why It Matters
- This funding supercharges BGC-515 clinical development and scales IMTAC™ screening for next-gen small molecules. → Source
🎯 Core Pain Point
- Data bottlenecks in chemoproteomics delay candidate ID
- Budget pressures for scaling clinical and R&D ops
💰 What to Pitch
- Primary: Integrated chemoproteomics informatics platform → accelerates binding site discovery by 30%
- Expansion: Clinical development management solution → streamlines multicenter trial workflows
🗺️ Quick Context
- HQ: San Jose, CA
- Employees: ≈ 75
- Rev: ≈ $3M
- Website: https://www.bridgenebio.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win BridGene Biosciences’s business.
- Benchling — R&D Cloud Platform
- Unique edge: Unified LIMS & ELN for bio teams
- Evaluated by Head of R&D for collaboration
- benchling.com
- Dotmatics — Scientific Informatics
- Unique edge: Comprehensive chemistry & biology data management
- Evaluated by CSO for platform depth
- dotmatics.com
- Veeva Systems — Clinical Trial Management
- Unique edge: Compliance-focused CTMS
- Evaluated by Head of Clinical Ops for trial readiness
- veeva.com
✅ Do-Now Checklist
Connect with Ping Cao on email to discuss the BridGene Biosciences sales trigger
Generate email + DM using the BridGene Biosciences sales trigger to showcase streamlined workflows
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get BridGene Biosciences sales trigger intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑Integrated chemoproteomics informatics platform❑
PROOF_METRIC = ❑accelerates binding site discovery by 30%❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Ping
COMPANY = BridGene Biosciences
DEPT = R&D
SIZE = 75
BOTTLENECK = data bottlenecks in chemoproteomics delay candidate ID
EVENT = $28M Series B+ financing round
DETAIL = $28M Series B+ financing
PAIN = Data bottlenecks in chemoproteomics delay candidate ID
SRC = https://vcnewsdaily.com/bridgene-biosciences/venture-capital-funding/zgjhqmkphm
SIM_CO = Benchling
WIN_METRIC = accelerated binding site discovery by 30%
NEXT_SIZE = 150
EMP_EST = ≈ 75
REV_EST = ≈ $3M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 75-person R&D
Ping—noticed your R&D team is ≈ 75.
That’s when data bottlenecks in chemoproteomics delay candidate ID slows growth.
We helped Benchling fix this with Integrated chemoproteomics informatics platform.
Result: accelerated binding site discovery by 30%.
Quick call?
PS—next bottleneck hits ≈ 150.
DM ≤45 words, TONE:
Saw your post about $28M Series B+ financing — Data bottlenecks in chemoproteomics delay candidate ID.
Integrated chemoproteomics informatics platform. accelerates binding site discovery by 30%.
Quick chat?